Toll Free: 1-888-928-9744
Published: Apr, 2014 | Pages:
38 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Merrion Pharmaceuticals Plc - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Merrion Pharmaceuticals Plc - Product Pipeline Review - 2014', provides an overview of the Merrion Pharmaceuticals Plc's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Merrion Pharmaceuticals Plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Merrion Pharmaceuticals Plc including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Merrion Pharmaceuticals Plc's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Merrion Pharmaceuticals Plc's pipeline products Reasons to buy - Evaluate Merrion Pharmaceuticals Plc's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Merrion Pharmaceuticals Plc in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Merrion Pharmaceuticals Plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Merrion Pharmaceuticals Plc and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Merrion Pharmaceuticals Plc - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Merrion Pharmaceuticals Plc and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Merrion Pharmaceuticals Plc Snapshot 5 Merrion Pharmaceuticals Plc Overview 5 Key Information 5 Key Facts 5 Merrion Pharmaceuticals Plc - Research and Development Overview 6 Key Therapeutic Areas 6 Merrion Pharmaceuticals Plc - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 Merrion Pharmaceuticals Plc - Pipeline Products Glance 12 Merrion Pharmaceuticals Plc - Late Stage Pipeline Products 12 Phase III Products/Combination Treatment Modalities 12 Merrion Pharmaceuticals Plc - Clinical Stage Pipeline Products 13 Phase II Products/Combination Treatment Modalities 13 Phase I Products/Combination Treatment Modalities 14 Merrion Pharmaceuticals Plc - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 Merrion Pharmaceuticals Plc - Drug Profiles 16 zoledronic acid 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 alendronate sodium 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 MER-104 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 fondaparinux sodium 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 GIPET Technology Based Program-1 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 GIPET Technology Based Program-2 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Partnered Program-1 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Partnered Program-2 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Partnered Program-3 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 UEA-1 Mimetics 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Merrion Pharmaceuticals Plc - Pipeline Analysis 28 Merrion Pharmaceuticals Plc - Pipeline Products by Target 28 Merrion Pharmaceuticals Plc - Pipeline Products by Route of Administration 30 Merrion Pharmaceuticals Plc - Pipeline Products by Molecule Type 31 Merrion Pharmaceuticals Plc - Pipeline Products by Mechanism of Action 32 Merrion Pharmaceuticals Plc - Recent Pipeline Updates 34 Merrion Pharmaceuticals Plc - Dormant Projects 35 Merrion Pharmaceuticals Plc - Locations And Subsidiaries 36 Head Office 36 Other Locations & Subsidiaries 36 Appendix 37 Methodology 37 Coverage 37 Secondary Research 37 Primary Research 37 Expert Panel Validation 37 Contact Us 38 Disclaimer 38
List of Tables Merrion Pharmaceuticals Plc, Key Information 5 Merrion Pharmaceuticals Plc, Key Facts 5 Merrion Pharmaceuticals Plc - Pipeline by Indication, 2014 7 Merrion Pharmaceuticals Plc - Pipeline by Stage of Development, 2014 8 Merrion Pharmaceuticals Plc - Monotherapy Products in Pipeline, 2014 9 Merrion Pharmaceuticals Plc - Partnered Products in Pipeline, 2014 10 Merrion Pharmaceuticals Plc - Partnered Products/ Combination Treatment Modalities, 2014 11 Merrion Pharmaceuticals Plc - Phase III, 2014 12 Merrion Pharmaceuticals Plc - Phase II, 2014 13 Merrion Pharmaceuticals Plc - Phase I, 2014 14 Merrion Pharmaceuticals Plc - Preclinical, 2014 15 Merrion Pharmaceuticals Plc - Pipeline by Target, 2014 29 Merrion Pharmaceuticals Plc - Pipeline by Route of Administration, 2014 30 Merrion Pharmaceuticals Plc - Pipeline by Molecule Type, 2014 31 Merrion Pharmaceuticals Plc - Pipeline Products by Mechanism of Action, 2014 33 Merrion Pharmaceuticals Plc - Recent Pipeline Updates, 2014 34 Merrion Pharmaceuticals Plc - Dormant Developmental Projects,2014 35 Merrion Pharmaceuticals Plc, Subsidiaries 36
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.